TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling

Ying Chen1, Jing Zhao1, Dengzhe Li1

  • 1Department of Hematology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, China.

Yonsei Medical Journal
|December 8, 2017
PubMed
Abstract

Insights

Tripartite-motif-containing protein 56 (TRIM56) acts as a tumor suppressor in multiple myeloma (MM). Its activation of the TLR3/TRIF pathway inhibits MM cell growth and promotes apoptosis, offering a potential therapeutic strategy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tripartite-motif-containing protein 56 (TRIM56) possesses known broad-spectrum antiviral properties linked to its E3 ligase activity.
  • The specific role and molecular mechanisms of TRIM56 in multiple myeloma (MM) pathogenesis remain largely unexplored.

Purpose of the Study:

  • To investigate the functional role of TRIM56 in multiple myeloma (MM).
  • To elucidate the underlying molecular mechanisms by which TRIM56 influences MM cell behavior and the associated signaling pathways.

Main Methods:

  • Quantitative real-time PCR and Western blot were used to assess TRIM56 expression levels in MM cells.
  • Cell proliferation and apoptosis were evaluated using MTT assays and flow cytometry.
  • Interferon-beta (IFN-β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels were quantified via ELISA.
  • The impact of TRIM56 on the toll-like receptor 3 (TLR3)/toll-IL-1 receptor (TIR) domain-containing adaptor inducing IFN-β (TRIF) signaling pathway was analyzed by Western blot.

Main Results:

  • TRIM56 expression was significantly reduced in multiple myeloma cells.
  • Overexpression of TRIM56 in U266 cells suppressed proliferation, induced apoptosis, and increased inflammatory cytokine production.
  • Knockdown of TRIM56 in RPMI8226 cells promoted cell growth, reduced apoptosis, and inhibited inflammatory cytokine secretion.
  • TRIM56 knockdown impaired the TLR3 signaling pathway, which was partially restored by TLR3 agonist poly (I:C).

Conclusions:

  • TRIM56 functions as a tumor suppressor in multiple myeloma.
  • The tumor-suppressive activity of TRIM56 is mediated through the activation of the TLR3/TRIF signaling pathway.
  • TRIM56 represents a potential therapeutic target for multiple myeloma treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.7K